Intellia Therapeutics, Inc. (0JBU.L)
USD 8.89
(-6.09%)
USD 8.89
(-6.09%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 96.74 Million USD | -15.15% |
| 2022 | 114.01 Million USD | 75.65% |
| 2021 | 64.91 Million USD | 93.14% |
| 2020 | 33.6 Million USD | 166.1% |
| 2019 | 12.63 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 87.33 Million USD | 0.0% |
| 2024 Q1 | 92.1 Million USD | 0.0% |
| 2023 Q3 | 101.26 Million USD | -4.09% |
| 2023 Q4 | 96.74 Million USD | -4.46% |
| 2023 FY | 96.74 Million USD | -15.15% |
| 2023 Q1 | 109.8 Million USD | -3.7% |
| 2023 Q2 | 105.58 Million USD | -3.84% |
| 2022 Q2 | 59.99 Million USD | -3.97% |
| 2022 Q1 | 62.48 Million USD | -3.75% |
| 2022 Q4 | 114.01 Million USD | 35.58% |
| 2022 FY | 114.01 Million USD | 75.65% |
| 2022 Q3 | 84.09 Million USD | 40.17% |
| 2021 Q2 | 63.25 Million USD | -1.9% |
| 2021 Q4 | 64.91 Million USD | -3.51% |
| 2021 Q1 | 64.48 Million USD | 91.87% |
| 2021 FY | 64.91 Million USD | 93.14% |
| 2021 Q3 | 67.27 Million USD | 6.35% |
| 2020 Q4 | 33.6 Million USD | 110.06% |
| 2020 FY | 33.6 Million USD | 166.1% |
| 2020 Q3 | 16 Million USD | -7.78% |
| 2020 Q2 | 17.34 Million USD | -7.07% |
| 2020 Q1 | 18.66 Million USD | 47.81% |
| 2019 Q1 | 15.13 Million USD | 0.0% |
| 2019 FY | 12.63 Million USD | 0.0% |
| 2019 Q4 | 12.63 Million USD | -10.69% |
| 2019 Q3 | 14.14 Million USD | -3.16% |
| 2019 Q2 | 14.6 Million USD | -3.49% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 83.688% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -3047.267% |
| Myriad Genetics, Inc. | 130.9 Million USD | 26.091% |
| Evolus, Inc. | 120.35 Million USD | 19.618% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 93.091% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 96.463% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -69.767% |
| uniQure N.V. | 130.06 Million USD | 25.616% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -111.733% |
| bluebird bio, Inc. | 224.41 Million USD | 56.89% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2097.796% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 95.871% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 75.056% |
| Dynavax Technologies Corporation | 252.41 Million USD | 61.672% |
| Editas Medicine, Inc. | 24.37 Million USD | -296.96% |
| FibroGen, Inc. | 89.69 Million USD | -7.86% |
| Geron Corporation | 35.05 Million USD | -176.018% |
| Blueprint Medicines Corporation | 610.96 Million USD | 84.165% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.253% |
| Illumina, Inc. | 1.48 Billion USD | 93.503% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -9574.7% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -182.969% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 62.545% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -160.921% |
| Adicet Bio, Inc. | 17.7 Million USD | -446.501% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 91.457% |
| Insmed Incorporated | 1.19 Billion USD | 91.893% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 95.103% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -311.007% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -191.442% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 98.797% |
| Waters Corporation | 2.3 Billion USD | 95.804% |
| Zoetis Inc. | 6.56 Billion USD | 98.526% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.691% |
| Biogen Inc. | 7.18 Billion USD | 98.654% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -188.668% |
| Nektar Therapeutics | 112.62 Million USD | 14.098% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -10236.218% |
| Perrigo Company plc | 3.63 Billion USD | 97.337% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 45.669% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 44.319% |
| Verastem, Inc. | 40.08 Million USD | -141.349% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 86.65% |
| Imunon, Inc. | 1.13 Million USD | -8391.845% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -2887.281% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 80.71% |
| Homology Medicines, Inc. | 43.17 Million USD | -124.076% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 96.421% |
| OPKO Health, Inc. | 222.03 Million USD | 56.427% |
| Exelixis, Inc. | 189.94 Million USD | 49.066% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 93.547% |
| TG Therapeutics, Inc. | 100.11 Million USD | 3.367% |
| Incyte Corporation | 29.16 Million USD | -231.757% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 78.332% |